Core Laboratories N.V. cash flow to debt ratio of 22.58% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Core Laboratories N.V.'s free cash flow has decreased 48.59% from $43.36M last year to $22.29M, signaling decreasing performance

Core Laboratories N.V.'s debt to equity ratio is 0.58, which means that the company's assets are healthy financed, signaling financial stability.

Core Laboratories N.V.'s debt has decreased relative to shareholder equity from 0.71 last year to 0.58 today, signaling strengthened financials

Core Laboratories N.V. has a net debt to EBITDA ratio of 1.99x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Core Laboratories N.V.'s interest coverage ratio of 3.51 indicates that earnings with good margin can cover interest payments on company debt

Core Laboratories N.V.'s profit margin was 5.99% last year and is 3.01% this year, signaling decreasing performance

Core Laboratories N.V.'s short-term assets of $214.66M exceed its short-term liabilities of $106.02M

Core Laboratories N.V.'s return on assets of 2.62% is lower than the 5.00% threshold, indicating inefficient asset utilization

Core Laboratories N.V.'s return on equity of 5.73%, is lower than 15.00%, indicating bad performance

Core Laboratories N.V.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Core Laboratories N.V. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Core Laboratories N.V. has positive free cash flow, indicating the company generates cash after capital expenditures

Core Laboratories N.V. has a free cash flow yield of 5.50%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Core Laboratories N.V.'s yearly earnings has decreased 5.51% since last year from $31.40M to $29.67M, signaling decreasing performance

Core Laboratories N.V.'s yearly revenue has increased 0.51% since last year from $523.85M to $526.52M, signaling increasing performance

ROIC 4.38% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Core Laboratories N.V.'s 3-year revenue CAGR of 2.44% is positive, indicating growing revenue over the past 3 years

Core Laboratories N.V. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Core Laboratories N.V. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Core Laboratories N.V. is overvalued relative to its fair value price of 3.57 based on Base Cash Flow Valuation (DCF) model

Core Laboratories N.V. has an earnings yield of 3.77%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Core Laboratories N.V. is overvalued relative to its fair value price of 7.67 based on Base EBITDA Valuation model

Core Laboratories N.V. has an EV/EBITDA ratio of 7.68x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Core Laboratories N.V. is undervalued relative to its fair value price of 9.53 based on Base Earnings Fair Value model

Core Laboratories N.V. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Core Laboratories N.V. has a price-to-book ratio of 1.45x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Core Laboratories N.V. has a price-to-sales ratio of 0.80x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue